Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus. The company is also developing FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; Mylan N.V.; and Actavis Laboratories. The company was founded in 2003 and is headquartered in Rehovot, Israel.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Phone972-8931-6233
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.67 million
Profitability
Miscellaneous
Employees75
OptionableOptionable
Foamix Pharmaceuticals (NASDAQ:FOMX) Frequently Asked Questions
What is Foamix Pharmaceuticals' stock symbol?
Foamix Pharmaceuticals trades on the NASDAQ under the ticker symbol "FOMX."
How were Foamix Pharmaceuticals' earnings last quarter?
Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) posted its earnings results on Wednesday, November, 7th. The specialty pharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.07. The specialty pharmaceutical company had revenue of $0.87 million for the quarter, compared to analyst estimates of $1.10 million. Foamix Pharmaceuticals had a negative return on equity of 118.29% and a negative net margin of 2,049.92%. View Foamix Pharmaceuticals' Earnings History.
When is Foamix Pharmaceuticals' next earnings date?
What price target have analysts set for FOMX?
4 Wall Street analysts have issued 1-year target prices for Foamix Pharmaceuticals' stock. Their predictions range from $11.00 to $30.00. On average, they expect Foamix Pharmaceuticals' share price to reach $17.6667 in the next year. This suggests a possible upside of 392.1% from the stock's current price. View Analyst Price Targets for Foamix Pharmaceuticals.
What is the consensus analysts' recommendation for Foamix Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foamix Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Foamix Pharmaceuticals.
Has Foamix Pharmaceuticals been receiving favorable news coverage?
Press coverage about FOMX stock has trended positive recently, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Foamix Pharmaceuticals earned a daily sentiment score of 2.3 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the near future.
Who are some of Foamix Pharmaceuticals' key competitors?
Some companies that are related to Foamix Pharmaceuticals include Canopy Rivers (RIV), Chromadex (CDXC), Mediwound (MDWD), Natural Alternatives International (NAII), Pharmacyte Biotech (PMCB), China Jo-Jo Drugstores (CJJD), Mannatech (MTEX), GLG Life Tech (GLGLF), Cyanotech (CYAN), FitLife Brands (FTLF), Tauriga Sciences (TAUG), True Drinks (TRUU), Nutra Pharma (NPHC), Entia Biosciences (ERGO) and Rock Creek Pharmaceuticals (RCPIQ).
Who are Foamix Pharmaceuticals' key executives?
Foamix Pharmaceuticals' management team includes the folowing people:
- Mr. David T. Domzalski, CEO & Director (Age 52)
- Mr. Ilan Hadar MBA, CFO & Country Mang. (Age 50)
- Mr. Yohan Hazot, VP of Pharmaceutical Devel. (Age 36)
- Dr. Darrell S. Rigel M.D., MS, Consultant (Age 69)
- Ms. Mutya Harsch, Gen. Counsel & Sr. VP of Legal Affairs
Who are Foamix Pharmaceuticals' major shareholders?
Foamix Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (8.59%), Great Point Partners LLC (7.46%), Stonepine Capital Management LLC (2.38%), Millennium Management LLC (1.94%), BlackRock Inc. (1.14%) and Tekla Capital Management LLC (1.11%). Company insiders that own Foamix Pharmaceuticals stock include Aharon Schwartz, Alvin D Howard, David Domzalski, Iain Stuart, Meir Eini, Russell P Elliott and Stanley Hirsch. View Institutional Ownership Trends for Foamix Pharmaceuticals.
Which institutional investors are selling Foamix Pharmaceuticals stock?
FOMX stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Bank of New York Mellon Corp, Tekla Capital Management LLC, First Manhattan Co., Millennium Management LLC, Squarepoint Ops LLC, UBS Oconnor LLC and Raymond James & Associates. Company insiders that have sold Foamix Pharmaceuticals company stock in the last year include Alvin D Howard, David Domzalski, Iain Stuart, Russell P Elliott and Stanley Hirsch. View Insider Buying and Selling for Foamix Pharmaceuticals.
Which institutional investors are buying Foamix Pharmaceuticals stock?
FOMX stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Stonepine Capital Management LLC, Knott David M, Diag Capital Management LP, BlackRock Inc., ETF Managers Group LLC, Eversept Partners LP and Great Point Partners LLC. View Insider Buying and Selling for Foamix Pharmaceuticals.
How do I buy shares of Foamix Pharmaceuticals?
Shares of FOMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Foamix Pharmaceuticals' stock price today?
One share of FOMX stock can currently be purchased for approximately $3.59.
How big of a company is Foamix Pharmaceuticals?
Foamix Pharmaceuticals has a market capitalization of $194.88 million and generates $3.67 million in revenue each year. The specialty pharmaceutical company earns $-65,710,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Foamix Pharmaceuticals employs 75 workers across the globe.
What is Foamix Pharmaceuticals' official website?
How can I contact Foamix Pharmaceuticals?
Foamix Pharmaceuticals' mailing address is 2 HOLZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 76704. The specialty pharmaceutical company can be reached via phone at 972-8931-6233 or via email at [email protected]
MarketBeat Community Rating for Foamix Pharmaceuticals (NASDAQ FOMX)
MarketBeat's community ratings are surveys of what our community members think about Foamix Pharmaceuticals and other stocks. Vote "Outperform" if you believe FOMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
